A Phase 4 interventional study of Nitro-Bid 2 % Topical Ointment in Gender Dysphoria, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-06.
Sponsored by University of Virginia · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Gender Dysphoria with a site in United States — 11 open to participants now, 13 under way, 3 of them phase 3. Gender Dysphoria · United States.
Among the 31 studies in Gender Dysphoria with a site in United States, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2022, is one of 4 in phase 4, reaches primary completion later than 0 of the 12 other live ones, and was the 23rd registered.
85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.
Browse Gender Dysphoria studies →11 of the 31 studies in Gender Dysphoria with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18–45 · Healthy volunteers
University Hospitals Cleveland Medical Center · Sites in United States
Ages 19–99 · Men only
Women and Infants Hospital of Rhode Island · Sites in United States
Ages 18+ · Women only
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Walter Reed National Military Medical Center · Sites in United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Gender Dysphoria studies recruiting now, 15 (48%) set no upper age limit and 10 (32%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 3 · Phase 4 4
First in 2017; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is above the median of 55 across 31 interventional studies indexed under Gender Dysphoria.
Median enrollment 50 across the 15 interventional studies, 46 across the 16 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
University of Virginia is the lead sponsor of 677 studies on the registry; 139 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.
University of Virginia has 1 study filed under Gender Dysphoria — fewer than ten, so there is no comparison to draw.
2 of the studies in Gender Dysphoria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07412509University of ChicagoCan 3D Modeling Enhance Patient Understanding, Education, and Surgical Outcomes in Gender Affirming Peritoneal Vaginoplasty? | 2027-03 |
| NCT07286123University Hospitals Cleveland Medical CenterGender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Gender Dysphoria with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nitropaste is a topical agent that contains 2% nitroglycerin. It is an effective vascular smooth dilator, with more powerful effect on venous vasculature than arterial vasculature. While its main indication is for angina pectoris, there have been many studies showing improved survival of axial and random pattern flaps. Furthermore, recent clinical studies highlight significantly decreased mastectomy flap wound complication and need for sharp debridement. Nitropaste has low rates of side effects and is very well tolerated in general. To this date, there's no study that investigates its utility on patients who are undergoing chest masculinizing surgery. The purpose of this study is to investigate the potential utility of nitropaste in reducing rates of wound complications in patients undergoing chest masculinizing surgery.
Nitropaste is a topical agent that contains 2% nitroglycerin. It is an effective vascular smooth dilator, with more powerful effect on venous vasculature than arterial vasculature. While its main indication is for angina pectoris, there have been many studies showing improved survival of axial and random pattern flaps. Furthermore, recent clinical studies highlight significantly decreased mastectomy flap wound complication and need for sharp debridement. Nitropaste has low rates of side effects and is very well tolerated in general. To this date, there's no study that investigates its utility on patients who are undergoing chest masculinizing surgery. The purpose of this study is to investigate the potential utility of nitropaste in reducing rates of wound complications in patients undergoing chest masculinizing surgery utilizing double incision with free nipple grafting technique. The investigators will conduct a prospective, randomized, single-blinded study and compare nitropaste vs. no nitropaste on mastectomy flaps. Nitropaste will be applied intraoperatively and the patients will not have to re-apply it. Follow up will occur on post-op day 5, 2 weeks, and 6 weeks during their routine postop visits. A study coordinator will document the condition of free nipple grafts and any other wounds at surgical site if present, which will be the primary outcome. Any complications including hematoma, seroma, infection, hypertrophic scarring, need for sharp debridement, 30 day ED visit or admission rates will be documented as secondary outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants get standard of care chest masculinizing surgery utilizing double incision and free nipple grafting surgery. They will get standard dressing applied, which includes Xeroform bolster over the nipple grafts + Tegederm over the bolster and surgical site and instructed not to remove the dressing until they come to clinic on POD5 for bolster take down.
Participants get standard of care chest masculinizing surgery utilizing double incision and free nipple grafting surgery. They will then get 2 packets of nitropaste applied (1 on each chest) around the free nipple graft and surgical sites. They will then get standard dressing applied, which includes Xeroform bolster over the nipple grafts + Tegederm over the bolster and surgical site and instructed not to remove the dressing until they come to clinic on POD5 for bolster take down.
Drug: Nitro-Bid 2 % Topical Ointment
Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
Free Nipple Graft Take
Rate of partial nipple graft loss (0-50%, 50% or more) or Complete nipple graft loss
Time frame: Will be assessed at 5 days, 2 weeks, 6 weeks post-op
Wounds
Rate of superficial wound, deep wound, delayed wound healing
Time frame: Will be assessed at 5 days, 2 weeks, 6 weeks post-op
Complications
hematoma, seroma, infection, hypertrophic scarring
Time frame: Will be tracked up until 3 months post-op
Sharp debridement
Need for any sharp debridement (office or OR)
Time frame: Will be tracked up until 3 months post-op
Revision
Need for any revision
Time frame: Will be tracked up until 3 months post-op
Readmission
30 day ED or inpatient admission rate
Time frame: Will be tracked 30 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Aug 2022 (actual). Primary completion is estimated for Aug 2025, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitroglycerin